Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation.
Hong LE, Wechalekar MD, Kutyna M, Small A, Lim K, Thompson-Peach C, Li JJ, Chhetri R, Scott HS, Brown A, Hahn CN, Yeung DT, Sajid S, Robinson N, Thomas R, Branford S, D'Andrea RJ, Samaraweera SE, Patnaik M, Proudman S, Thomas D, Kok CH, Shah MV, Hiwase DK. Hong LE, et al. Among authors: chhetri r. Blood. 2024 May 2;143(18):1873-1877. doi: 10.1182/blood.2023023593. Blood. 2024. PMID: 38457663 Free article.
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
Shah MV, Tran ENH, Shah S, Chhetri R, Baranwal A, Ladon D, Shultz C, Al-Kali A, Brown AL, Chen D, Scott HS, Greipp P, Thomas D, Alkhateeb HB, Singhal D, Gangat N, Kumar S, Patnaik MM, Hahn CN, Kok CH, Tefferi A, Hiwase DK. Shah MV, et al. Among authors: chhetri r. Blood Cancer J. 2023 Apr 11;13(1):51. doi: 10.1038/s41408-023-00821-x. Blood Cancer J. 2023. PMID: 37041128 Free PMC article.
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.
Singhal D, Wee LYA, Kutyna MM, Chhetri R, Geoghegan J, Schreiber AW, Feng J, Wang PP, Babic M, Parker WT, Hiwase S, Edwards S, Moore S, Branford S, Kuzmanovic T, Singhal N, Gowda R, Brown AL, Arts P, To LB, Bardy PG, Lewis ID, D'Andrea RJ, Maciejewski JP, Scott HS, Hahn CN, Hiwase DK. Singhal D, et al. Among authors: chhetri r. Leukemia. 2019 Dec;33(12):2842-2853. doi: 10.1038/s41375-019-0479-8. Epub 2019 May 14. Leukemia. 2019. PMID: 31089247
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies.
Saygin C, Roloff G, Hahn CN, Chhetri R, Gill S, Elmariah H, Talati C, Nunley E, Gao G, Kim A, Bishop M, Kosuri S, Das S, Singhal D, Venugopal P, Homan CC, Brown A, Scott HS, Hiwase D, Godley LA. Saygin C, et al. Among authors: chhetri r. Blood Adv. 2023 Feb 28;7(4):549-554. doi: 10.1182/bloodadvances.2022008172. Blood Adv. 2023. PMID: 36001442 Free PMC article.
TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.
Hiwase D, Hahn C, Tran ENH, Chhetri R, Baranwal A, Al-Kali A, Sharplin K, Ladon D, Hollins R, Greipp P, Kutyna M, Alkhateeb H, Badar T, Wang P, Ross DM, Singhal D, Shanmuganathan N, Bardy P, Beligaswatte A, Yeung D, Litzow MR, Mangaonkar A, Giri P, Lee C, Yong A, Horvath N, Singhal N, Gowda R, Hogan W, Gangat N, Patnaik M, Begna K, Tiong IS, Wei A, Kumar S, Brown A, Scott H, Thomas D, Kok CH, Tefferi A, Shah MV. Hiwase D, et al. Among authors: chhetri r. Blood. 2023 Mar 2;141(9):1087-1091. doi: 10.1182/blood.2022018236. Blood. 2023. PMID: 36574363 Free article. No abstract available.
Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.
Shah MV, Chhetri R, Dholakia R, Kok CH, Gangat N, Alkhateeb HB, Al-Kali A, Patnaik MM, Baranwal A, Greipp PT, He R, Begna KH, Tiong IS, Wei AH, Hiwase D. Shah MV, et al. Among authors: chhetri r. Am J Hematol. 2022 Aug;97(8):1013-1022. doi: 10.1002/ajh.26589. Epub 2022 May 27. Am J Hematol. 2022. PMID: 35560061 Free PMC article.
A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data.
Sharplin K, Proudman W, Chhetri R, Tran ENH, Choong J, Kutyna M, Selby P, Sapio A, Friel O, Khanna S, Singhal D, Damin M, Ross D, Yeung D, Thomas D, Kok CH, Hiwase D. Sharplin K, et al. Among authors: chhetri r. Cancers (Basel). 2023 Aug 8;15(16):4019. doi: 10.3390/cancers15164019. Cancers (Basel). 2023. PMID: 37627047 Free PMC article.
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer.
Singhal D, Hahn CN, Feurstein S, Wee LYA, Moma L, Kutyna MM, Chhetri R, Eshraghi L, Schreiber AW, Feng J, Wang PP, Babic M, Parker WT, Gao S, Moore S, Das S, Thomas D, Pattnaik S, Brown AL, D'Andrea RJ, Poplawski NK, Thomas D, Scott HS, Godley LA, Hiwase DK. Singhal D, et al. Among authors: chhetri r. Leukemia. 2021 Nov;35(11):3245-3256. doi: 10.1038/s41375-021-01246-w. Epub 2021 Apr 13. Leukemia. 2021. PMID: 33850299
75 results